Showing 2,281 - 2,300 results of 48,331 for search '(( 12 we decrease ) OR ( 50 ((((mean decrease) OR (teer decrease))) OR (a decrease)) ))', query time: 1.18s Refine Results
  1. 2281
  2. 2282
  3. 2283
  4. 2284
  5. 2285
  6. 2286

    Behavioral and subjective data. by Mehran Emadi Andani (732166)

    Published 2015
    “…<p>A) Force profile (average of 50 trials) of the baseline (dashed lines) and final (solid lines) sessions in one subject of the experimental group (red lines) and one subject of the control group (green lines). …”
  7. 2287
  8. 2288
  9. 2289
  10. 2290
  11. 2291
  12. 2292
  13. 2293
  14. 2294
  15. 2295

    Fold change in EC<sub>50</sub> in all polyene resistant lines of <i>Leishmania spp</i>. by Edubiel A. Alpizar-Sosa (13848145)

    Published 2022
    “…Values higher and lower than 1, indicate a decrease and rise in susceptibility relative to the parental line, respectively. …”
  16. 2296

    Serum Creatinine Modifies Associations between Body Mass Index and Mortality and Morbidity in Prevalent Hemodialysis Patients by Yukitoshi Sakao (2547880)

    Published 2016
    “…A total of 119,099 patients were selected (age: 65±12 years; median time on HD: 5.6 years; male: 62%), and we examined the association of basal BMI with mortality and morbidity after a 1-year period. …”
  17. 2297
  18. 2298
  19. 2299
  20. 2300

    Structure–Activity Studies of 1<i>H</i>‑Imidazo[4,5‑<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators by Lucas B. Fallot (14106171)

    Published 2022
    “…Although having low Caco-2 permeability and high plasma protein binding, hydrophobic 2-cyclohept-4-enyl-<i>N</i>-3,4-dichlorophenyl, MRS7788 <b>18</b>, and 2-heptan-4-yl-<i>N</i>-4-iodophenyl, MRS8054 <b>39</b>, derivatives were orally bioavailable in rat. 2-Heptan-4-yl-<i>N</i>-3,4-dichlorophenyl <b>14</b> and 2-cyclononyl-<i>N</i>-3,4-dichlorophenyl <b>20</b> derivatives and <b>39</b> greatly enhanced Cl-IB-MECA-stimulated [<sup>35</sup>S]GTPγS binding <i>E</i><sub>max</sub>, with only <b>12b</b> trending toward decreasing the agonist EC<sub>50</sub>. …”